Associated tags: Strategic planning, Physician, Prescription, Prevalence, Pharmacy, Therapy, Degenerative disease, Skin, Research, Practitioner, Ageing, Food and Drug Administration, Intelligence, Atopic dermatitis, Fine chemical, Pharmaceutical industry, XETRA, Inflammation, The Group, U.S. FDA
Locations: SINGAPORE, UNITED KINGDOM, ITALY, EUROPE, SPAIN, GERMANY, UNITED STATES
Cream,
TNF,
EUR,
Psoriasis,
Agreement,
Inflammation,
Patient,
PAD,
Dermatology,
MC2,
Skin,
Gold,
Comorbidity,
Safety,
Good,
Pharmaceutical industry SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
Key Points:
- SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
- Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
- Wynzora® Cream ( www.wynzora.com ), is a leading topical treatment for plaque psoriasis, including scalp psoriasis in adults.
- "Hyphens Pharma is a leading specialty pharma company focused on the commercialisation of innovative pharmaceutical products in the ASEAN region.
Cream,
TNF,
EUR,
Psoriasis,
Agreement,
Inflammation,
Patient,
PAD,
Dermatology,
MC2,
Skin,
Gold,
Comorbidity,
Safety,
Good,
Pharmaceutical industry SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
Key Points:
- SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
- Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
- Wynzora® Cream ( www.wynzora.com ), is a leading topical treatment for plaque psoriasis, including scalp psoriasis in adults.
- "Hyphens Pharma is a leading specialty pharma company focused on the commercialisation of innovative pharmaceutical products in the ASEAN region.
Retrieved on:
Friday, December 23, 2022
Strategic planning,
The Group,
C43,
Exocrine gland,
IQVIA,
Dermatology,
Patient,
GI,
U.S. FDA,
Digital,
Hair loss,
Medtronic,
Acne,
Hyperpigmentation,
Marketing,
Endoscopy,
FDA,
Cancer,
Inflammation,
Practitioner,
XETRA,
Prescription,
Prevalence,
Partnership,
Pharmacy,
Therapy,
Degenerative disease,
Skin,
Physician,
Research,
Ageing,
Food and Drug Administration,
Intelligence,
Atopic dermatitis,
Fine chemical,
Pharmaceutical industry,
ASEAN SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
Key Points:
- SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
- Lim See Wah, Executive Chairman and CEO of Hyphens Pharma, said: "Acne is a medical condition that affects millions in the ASEAN region.
- We would like to thank Cosmo for this partnership and their confidence in Hyphens Pharma.
- Hyphens Pharma International Limited and its subsidiaries (the "Group") is Singapore's leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprint in ASEAN countries.
Retrieved on:
Friday, December 23, 2022
Strategic planning,
The Group,
C43,
Exocrine gland,
IQVIA,
Dermatology,
Patient,
GI,
U.S. FDA,
Digital,
Hair loss,
Medtronic,
Acne,
Hyperpigmentation,
Marketing,
Endoscopy,
FDA,
Cancer,
Inflammation,
Practitioner,
XETRA,
Prescription,
Prevalence,
Partnership,
Pharmacy,
Therapy,
Degenerative disease,
Skin,
Physician,
Research,
Ageing,
Food and Drug Administration,
Intelligence,
Atopic dermatitis,
Fine chemical,
Pharmaceutical industry,
ASEAN SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
Key Points:
- SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
- Lim See Wah, Executive Chairman and CEO of Hyphens Pharma, said: "Acne is a medical condition that affects millions in the ASEAN region.
- We would like to thank Cosmo for this partnership and their confidence in Hyphens Pharma.
- Hyphens Pharma International Limited and its subsidiaries (the "Group") is Singapore's leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprint in ASEAN countries.
